Drug Trial Radar · NCT07941609
A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Dec 16, 2028
Study completion Dec 22, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Dato-DXdDrug
Treatment A/B: Dato-DXd as IV infusion.
DurvalumabDrug
Treatment A/B: Durvalumab as IV infusion
CarboplatinDrug
Treatment B: Carboplatin as IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS as assessed by investigator on Treatment ATime frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
- PFS as assessed by investigator on Treatment BTime frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
Locations
87 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Irvine, California
Research Site
Oakland, California
Research Site
Golden, Colorado
Research Site
New Haven, Connecticut
Research Site
Miami, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Peoria, Illinois
Research Site
Greer, South Carolina
Research Site
Greer, South Carolina
Research Site
Sugar Land, Texas
Research Site
Salt Lake City, Utah
Research Site
Morgantown, West Virginia
Research Site
Ciudad Autonoma Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Rioja, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
San Juan, Argentina
Research Site
Viedma, Argentina
Research Site
Adelaide, Australia
Research Site
Bedford Park, Australia
Research Site
Southport, Australia
Research Site
Waratah, Australia
Research Site
Woodville, Australia
Research Site
Blumenau, Brazil
Research Site
Curitiba, Brazil
Research Site
Ijuí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Santa Maria, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Teresina, Brazil
Research Site
Vitória, Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Brampton, Ontario, Canada
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.